# Effect of Cyclosporine on the Pharmacokinetics (PK) of AT-527 (R07496998)

> **NCT04849299** · PHASE1 · COMPLETED · sponsor: **Atea Pharmaceuticals, Inc.** · enrollment: 24 (actual)

## Conditions studied

- Healthy Volunteer Study

## Interventions

- **DRUG:** AT-527 550 mg + cyclosporine
- **DRUG:** AT-527 550 mg + cyclosporine

## Key facts

- **NCT ID:** NCT04849299
- **Lead sponsor:** Atea Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-04-18
- **Primary completion:** 2021-05-10
- **Final completion:** 2021-05-10
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2021-08-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04849299

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04849299, "Effect of Cyclosporine on the Pharmacokinetics (PK) of AT-527 (R07496998)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04849299. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*